Celleron licenses cancer lead from AstraZeneca
This article was originally published in Scrip
UK-based Celleron Therapeutics has secured exclusive rights to AstraZeneca's histone deacetylase inhibitor AZD-9468. Celleron plans to develop the drug (now to be known as CXD101) in conjunction with their "CancerNav" predictive biomarker platform, which they hope can be used to identify susceptible tumours. Celleron will lead the clinical trials, which have yet to start, and AstraZeneca will receive significant milestones, royalties and additional share of financial proceeds in the event of successful commercialisation by a third party.